These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 7769190)
81. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. Bermejo F; Aguas M; Chaparro M; Domènech E; Echarri A; García-Planella E; Guerra I; Gisbert JP; López-Sanromán A; Gastroenterol Hepatol; 2018 Mar; 41(3):205-221. PubMed ID: 29357999 [TBL] [Abstract][Full Text] [Related]
86. How effective are the usual treatments for Crohn's disease? Bebb JR; Scott BB Aliment Pharmacol Ther; 2004 Jul; 20(2):151-9. PubMed ID: 15233694 [TBL] [Abstract][Full Text] [Related]
87. [Current medical treatment of inflammatory bowel disease]. Bosques-Padilla F Rev Gastroenterol Mex; 2007 Nov; 72 Suppl 2():92-101. PubMed ID: 18277494 [No Abstract] [Full Text] [Related]
88. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Faubion WA; Loftus EV; Harmsen WS; Zinsmeister AR; Sandborn WJ Gastroenterology; 2001 Aug; 121(2):255-60. PubMed ID: 11487534 [TBL] [Abstract][Full Text] [Related]
89. Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling. Kimura K; Yoshida A; Katagiri F; Takayanagi R; Yamada Y Biopharm Drug Dispos; 2019 Jul; 40(7):250-261. PubMed ID: 31256430 [TBL] [Abstract][Full Text] [Related]
90. The Effect of Low-Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental Before-and-After Prescription Database Study. Raknes G; Simonsen P; Småbrekke L J Crohns Colitis; 2018 May; 12(6):677-686. PubMed ID: 29385430 [TBL] [Abstract][Full Text] [Related]
91. Approach to steroid-dependent and steroid-refractory Crohn's disease. Lichtenstein GR J Pediatr Gastroenterol Nutr; 2001 Sep; 33 Suppl 1():S27-35. PubMed ID: 11685972 [No Abstract] [Full Text] [Related]
92. [Chronic inflammatory bowel diseases. Pathophysiology and drug therapy]. von Ritter C Radiologe; 1998 Jan; 38(1):3-7. PubMed ID: 9530772 [TBL] [Abstract][Full Text] [Related]
93. Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Herrlinger KR; Noftz MK; Fellermann K; Schmidt K; Steinhoff J; Stange EF Aliment Pharmacol Ther; 2001 Mar; 15(3):363-9. PubMed ID: 11207511 [TBL] [Abstract][Full Text] [Related]
94. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers. Norlander B; Gotthard R; Ström M Aliment Pharmacol Ther; 1990 Oct; 4(5):497-505. PubMed ID: 2129637 [TBL] [Abstract][Full Text] [Related]
95. Clinical perspectives in inflammatory bowel disease. Selby W Aust N Z J Med; 1996 Feb; 26(1):15-9. PubMed ID: 8775523 [No Abstract] [Full Text] [Related]
96. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Fagan EA; Dyck RF; Maton PN; Hodgson HJ; Chadwick VS; Petrie A; Pepys MB Eur J Clin Invest; 1982 Aug; 12(4):351-9. PubMed ID: 6814926 [TBL] [Abstract][Full Text] [Related]